Therapeutic Area | MeSH |
---|---|
mental disorders | D001523 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
SEROQUEL | AstraZeneca | N-020639 RX | 1997-09-26 | 6 products, RLD |
SEROQUEL XR | AstraZeneca | N-022047 RX | 2007-05-17 | 5 products, RLD |
Brand Name | Status | Last Update |
---|---|---|
quetiapine | ANDA | 2024-12-31 |
quetiapine fumarate | ANDA | 2024-12-31 |
quetiapine fumarate er | ANDA | 2024-10-02 |
seroquel | New Drug Application | 2022-01-27 |
seroquel xr | 2008-01-17 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | 1 | 1 | 1 | 3 |
Psychotic disorders | D011618 | — | F20.81 | — | — | 1 | 1 | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | — | — | 1 | 1 |
Syndrome | D013577 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Quetiapine |
INN | quetiapine |
Description | Quetiapine is a dibenzothiazepine, a N-alkylpiperazine and a N-arylpiperazine. It has a role as a serotonergic antagonist, a dopaminergic antagonist, a histamine antagonist, an adrenergic antagonist and a second generation antipsychotic. |
Classification | Small molecule |
Drug class | tricyclic compounds; antipsychotics (dibenzothiazepine derivatives) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1 |
PDB | — |
CAS-ID | 111974-69-7 |
RxCUI | — |
ChEMBL ID | CHEMBL716 |
ChEBI ID | 8707 |
PubChem CID | 5002 |
DrugBank | DB01224 |
UNII ID | BGL0JSY5SI (ChemIDplus, GSRS) |